Thanks, this made me go have a look at competitor pipelines. I was a bit sceptical about PTX 100 being a large driver of growth, but after looking at the broad scope that is being applied when just targeting KRASG12C + G12D, I reckon I was pretty wrong especially if it plays well with other therapies.
Found this Miranti presentation interesting for context
https://s27.q4cdn.com/140416303/files/doc_presentation/2021/09/Mirati_Corporate-Presentation_20September2021_FINAL_PDF.pptx.pdf
Ann: PTX-100 trial advances following successful Phase 1b, page-288
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
-0.001(2.50%) |
Mkt cap ! $31.40M | |||
| Open | High | Low | Value | Volume |
| 4.1¢ | 4.1¢ | 3.9¢ | $72.73K | 1.802M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 436541 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.1¢ | 560576 | 1 |
View Market Depth
| Last trade - 15.59pm 15/11/2024 (20 minute delay) ? |
| PTX (ASX) Chart |